Principal Financial Group Inc. Acquires 44,777 Shares of Cryolife Inc (CRY)

Principal Financial Group Inc. increased its holdings in shares of Cryolife Inc (NYSE:CRY) by 21.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 258,323 shares of the medical equipment provider’s stock after acquiring an additional 44,777 shares during the quarter. Principal Financial Group Inc. owned about 0.77% of Cryolife worth $5,864,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue increased its position in Cryolife by 80.8% during the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 2,407 shares during the period. First Mercantile Trust Co. increased its position in Cryolife by 5.6% during the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after acquiring an additional 291 shares during the period. Municipal Employees Retirement System of Michigan increased its position in Cryolife by 3.7% during the second quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock worth $127,000 after acquiring an additional 230 shares during the period. Creative Planning increased its position in Cryolife by 3.0% during the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after acquiring an additional 200 shares during the period. Finally, Victory Capital Management Inc. increased its position in Cryolife by 17.7% during the second quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock worth $138,000 after acquiring an additional 1,041 shares during the period. 73.31% of the stock is currently owned by institutional investors and hedge funds.

Cryolife Inc (NYSE:CRY) opened at $18.95 on Friday. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29. Cryolife Inc has a 1-year low of $14.02 and a 1-year high of $24.00. The company has a market cap of $639.04, a PE ratio of 46.58 and a beta of 0.81.

Cryolife (NYSE:CRY) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same period last year, the firm earned $0.13 EPS. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. equities research analysts predict that Cryolife Inc will post 0.28 earnings per share for the current year.

In other Cryolife news, Director James Benson sold 2,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $22.80, for a total value of $45,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Amy Horton sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $76,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 98,705 shares in the company, valued at $1,875,395. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,190 shares of company stock worth $1,163,840. Insiders own 6.00% of the company’s stock.

A number of equities analysts recently commented on CRY shares. Lake Street Capital raised their price target on shares of Cryolife to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, October 11th. TheStreet lowered shares of Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Zacks Investment Research lowered shares of Cryolife from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Northland Securities reaffirmed a “buy” rating and set a $23.50 price target on shares of Cryolife in a research report on Monday, November 13th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 price target on shares of Cryolife in a research report on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $23.63.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://ledgergazette.com/2017/12/09/principal-financial-group-inc-acquires-44777-shares-of-cryolife-inc-cry.html.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply